BioNTech (BNTX) Q2 FY26 earnings call

BioNTech announced the appointment of Guido Oelkers as its new CEO, signaling a strategic evolution towards becoming a multiproduct biopharmaceutical company by 2030. The quarter featured significant pipeline progress, with promising Phase II data for pumitamig in NSCLC and gotistobart in squamous NSCLC, reinforcing confidence in their oncology strategy. Despite a downward revision to full-year revenue guidance due to softer COVID-19 vaccine demand, the company maintains a robust financial position to fund its late-stage pipeline and strategic investments.